Form 8-K - Current report:
SEC Accession No. 0001193125-21-209282
Filing Date
2021-07-07
Accepted
2021-07-07 08:02:02
Documents
12
Period of Report
2021-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d145110d8k.htm   iXBRL 8-K 27329
  Complete submission text file 0001193125-21-209282.txt   154140

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA svra-20210702.xsd EX-101.SCH 2902
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE svra-20210702_lab.xml EX-101.LAB 18906
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE svra-20210702_pre.xml EX-101.PRE 11869
5 EXTRACTED XBRL INSTANCE DOCUMENT d145110d8k_htm.xml XML 3518
Mailing Address 900 S. CAPITAL OF TEXAS HIGHWAY SUITE 150 AUSTIN TX 78746
Business Address 900 S. CAPITAL OF TEXAS HIGHWAY SUITE 150 AUSTIN TX 78746 512-614-1848
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

IRS No.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32157 | Film No.: 211076255
SIC: 2834 Pharmaceutical Preparations